



Intercell appoints new Scientific Advisory Board

Vienna (Austria), February 14, 2006 – Intercell AG announced today the appointment of its new Scientific Advisory Board (SAB). The company feels honored that the following academic scientists have accepted the invitation to serve in Intercell's new SAB: Rafi Ahmed (Emory University School of Medicine), Hubert Blum (University of Freiburg), Stanley N. Cohen (Stanford University), Franz Xaver Heinz (University of Vienna), Stefan H.E. Kaufmann (Max-Planck-Institute for Infection Biology), Staffan Normark (Karolinska Institute) and Hans Wigzell (Karolinska Institute).

Throughout Intercell's next growth stage, the new members will support the company with their broad knowledge and unique expertise in the fields of infectious diseases, microbiology, immunology and molecular biology as well as their worldwide networks. The new SAB will follow the original SAB that has been pivotal to launch the company eight years ago and that has accompanied Intercell on its way from a university spin-off to an internationally acknowledged vaccine player in the biotech arena.

The former SAB, chaired by Intercell's co-founder Max Birnstiel, included Hubert Blum, David Hirsh, Staffan Normark, Hamilton Smith, Hans Strander and Charles Weissmann. They have added much to Intercell's credibility, helped to implement high scientific standards and supported the company in finding its strategic focus. The new SAB will also give assistance to Intercell by offering the advice of outstanding scientists, with the company's primary focus on vaccines and immunotherapeutic treatments against infectious diseases.

Intercell's CSO, Alexander von Gabain, states: "I would like to thank the members of the founding SAB for their long-time commitment to our company and their outstanding contribution to create an excellent position in science and product development. I welcome the new SAB members who perfectly match the scientific profile that we need to develop the company into its next stage."

Max Birnstiel, co-founder and Chair of the founding SAB, states: "I am delighted that the new SAB members will continue our mission to support building excellence in biotech. Their competence, skills, and reputation is optimal for reaching Intercell's strategic goal to fight infectious diseases and also to achieving state of the art vaccine technologies."

About Intercell AG

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for prevention and treatment of diseases for which there exists substantial unmet medical need. The Company develops antigens and immunizers (adjuvants) which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for





Japanese Encephalitis in Phase III, a vaccine for Hepatitis C in Phase II, partnered vaccines for Tuberculosis and *S. aureus* which are in Phase I and five products focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2

A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

Be invited to: www.intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.